Literature DB >> 28377898

BMP15 and GDF9 Gene Mutations in Premature Ovarian Failure.

Ravindra Kumar1, Madhuri Alwani2, Susmit Kosta1, Ravjyot Kaur2, Sarita Agarwal3.   

Abstract

BACKGROUND: Premature ovarian failure (POF) is an ovarian defect characterized by the premature depletion of ovarian follicles before the age of 40, representing one major cause of female infertility. Mutations in bone morphogenetic protein 15 (BMP15) and growth differentiation factor 9 (GDF9) have been shown to be associated with POF.
METHODS: Genomic DNA was isolated from 52 idiopathic premature ovarian failure patients and 100 normal control individuals. Exons of BMP15 and GDF9 gene were amplified using PCR method and subjected to directed sequencing. Variants were identified by comparing the sequences obtained with normal sequences from NCBI database.
RESULTS: Four BMP15 gene variants were identified in 6 patients in heterozygous condition. Out of these 4 variants, 3 variants namely, c.165A>T (p.Glu55Asp), c.538 G>T (p.Aln180 Ser) and c. 510_512 delT were novel variants. In silico analysis using SIFT, Provean and Polyphen 2 score predicted the non-deleterious effect of c.165A>T and c.538 G>T variant. 788insTCT variant was identified in 3 patients. No variant was identified in GDF9 gene in any patients and controls.
CONCLUSION: Although the variant has been identified in BMP15 gene but it may not be associated with the premature ovarian failure.

Entities:  

Keywords:  Bone morphogenetic protein 15; Female infertility; Gene mutation; Growth differentiation factor 9; Premature ovarian failure

Year:  2017        PMID: 28377898      PMCID: PMC5359856     

Source DB:  PubMed          Journal:  J Reprod Infertil        ISSN: 2228-5482


Introduction

Premature ovarian failure (POF) is characterized by hyper gonadotropic ovarian deficiency with primary or secondary amenorrhoea (1). It affects 0.0001% of females by the age of 20 years, 0.001% by 30 years and 0.01% by 40 years, showing the one major cause of female infertility (2). Ovarian function is regulated by a combined stimulus of gonadotropins, follicular stimulating hormone (FSH), luteinizing hormone, and local ovarian factors such as inhibins, activins, bone morphogenetic protein 15 (BMP15) and growth differentiation factor 9 (GDF9). A familial accumulation of the POF syndrome has been observed in between 4 and 31% of the patients with POF which suggests dominant genetic etiology (3). BMP15 and GDF9 belong to transforming growth factor-β (TGF-β) superfamily (4, 5). Genes belonging to TGF β superfamily regulate many aspects of development by activating transmembrane serine/threonine kinase receptors (6). BMP15 has been shown to stimulate granulosa cell growth and promotes the progression of folliculogenesis from the primary stage to the follicle stimulating hormone (FSH) dependent stage (7–9). Mutations in BMP15 gene have been found as a culprit for POF in several worldwide cohorts with a variable prevalence between 1.5 and 12% (10–12). However, Zhang et al. (13) and Ledig et al. (14) failed to find any association between BMP15 and POF. GDF9 is also expressed in the oocyte and its products can form noncovalent heterodimers acting in a synergistic manner on the function of surrounding follicular granulosa cells (15). GDF9 gene variations in humans described so far in different ethnicities are all heterozygous, affect exclusively the pro-region with a prevalence of 1.4%, and are not detected in the control samples (16–18). Due to these conflicting results of various studies, this study was planned to evaluate the association between growth differentiation factor 9 (GDF9) and bone morphogenetic protein 15 (BMP15) genes mutations with premature ovarian failure.

Methods

Subjects:

Patients with a diagnosis of POF were recruited from the Department of Obstetrics and Gynaecology, Sri Aurobindo Medical Collage and PG Institute, Indore during the period between September 2012 and March 2015. A total of 52 patients with idiopathic premature ovarian failure or insufficiency subjects with 46XX karyotype were enrolled in the present study. The patients had a mean age of 29.82±6.0 years (range, 17–39 years). Less than 40 year old healthy individuals visiting the department for routine investigations were selected as the control group. All the control individuals had a regular menstrual cycle, and normal reproductive hormone levels and chromosomes. The inclusion criteria of all participants were ≤40 years of age, duration of amenorrhea ≥6 months, serum FSH level ≥40 IU/l on two or more occasions with the presence of amenorrhea. Individuals with a history of ovarian surgery, radiotherapy, chemotherapy or other factors, which may damage ovarian functions, were excluded. The present study was approved by the Ethics Review Committee of the Sri Aurobindo Medical Collage and PG Institute. Written informed consent was obtained from all participants following a detailed description of the potential benefits of the investigation.

DNA extraction, sequencing and analysis:

All the laboratory investigations were performed in Central Research Laboratory of the institute; 5 ml venous blood sample was drawn in EDTA vacutainer. Genomic DNA was extracted from the blood using a QIAamp DNA isolation kit according to the manufacturer’s instructions, and the concentration was determined using Qubit Fluorometer (Life Technologies). PCR amplification of the GDF9 and BMP15 genes was performed using the primers shown in table 1, in a 50 μl reaction volume containing 50 nmol DNA template, 200 nmol dNTP, 10 pmol forward and reverse primers, 1 U Taq DNA polymerase and ddH2O, under the PCR amplification conditions shown in table 1. The PCR products were purified by DNA purification kit and subjected to direct sequencing using big dye terminator kit 3.1 (Applied Biosystems).
Table 1.

Primers and protocols used for PCR amplification of GDF9 and BMP15

GeneLocationPrimer sequencePCR amplification protocol
GDF9
Exon 1F,5′-TAGTCCACCCACACACCTGA-3′;R,5′-CCAGAAGCCTGAGAACCA -3′F,5′-TTCCTCCTTTGGTTTTGCTG-3′;R,5′-AAAGCTCTGGAGTCTGGCTG -3′F,5′-TTCTATCTGTTGGGCGAGGT-3′;R,5′-CATCTTCCCTCCACCCAGT-3′F, 5′-CTGCCTGTTGTGTTGACTGA-3′;R,5′-TCTGAATCCATTTGTGTTTCTTTC-3′94°C for 5 min, followed by 30 cycles at 94°C for 30 s, 58°C for 30 s and 72°C for 30 s, then finally 72°C for 7 min
Exon 2F,5′-CTCTCGGCAGAGCTCCATAC-3′;R,5′-GGGGACACCAGAGTCATGTT-3′F,5′-CGCAGAGGTCAGGAAACTGT-3′;R,5′-GGTCTTGGCACTGAGGAGTC-3′F,5′-TGAAAGACCAGCTGGAGCA-3′;R,5′-TCAGATTGAAGGAAGCTGGG-3′F,5′-TCGGTATGGCTCTCCAGTTC-3′;R,5′-AATATATCAAGCTTTCTCTTGAAG-3′94°C for 5 min, followed by 30 cycles at 94°C for 30 s, 58°C for 30 s and 72°C for 30 s, then finally 72°C for 7 min
BMP15
Exon 1F, 5′-TTGTGTTGGGGCCTGTTGTT-3′;R,5′-GGTACAACTCCAGCATGTACC-3′F,5′-GCTGCTAGAAGAATCCCCTG-3′;R,5′-AACCCACCAATTCCCTTTT-3′94°C for 5 min, followed by 30 cycles at 94°C for 60 s, 58°C for 60 s and 72°C for 60 s, then finally 72°C for 7 min
Exon 2F,5′-AATATTCATGTTAAGAGGTAAGA-3′;R,5′-AGGAAGGGAAGTGGTTGGTT-3′F,5′-TCAATCTCTCCTGCCATGTGG-3′;R,5′-TGTCCAAGGATGAAGAGCC -3′F,5′-TGGTCTTGAGCTCTGGCATG-3′;R,5′-CTGATTTGGAAAGGGTGGAG-3′94°C for 5 min, followed by 30 cycles at 94°C for 30 s, 58°C for 30 s and 72°C for 30 s, then finally 72°C for 7 min
Primers and protocols used for PCR amplification of GDF9 and BMP15 The sequencing chromatograms were assessed using the ABI sequence scanner program and the sequences of the GDF9 and BMP15 genes were aligned to those registered in Gene Bank (http://www.ncbi.nlm.nih.gov/genbank/) for the identification of mutant loci. To determine the potentially deleterious effect of the amino acid changes, Provean software (http://provean.jcvi.org/index.php), SIFT software (http://sift.jcvi.org) and Polyphen 2 software (http://genetics.bwh.harvard.edu/pph2/) were used. Provean software predicts whether an amino acid substitution or indel has an impact on the biological function of a protein (19). The SIFT software predicts whether an amino acid substitution affects protein function based on sequence homology and the physical properties of amino acids (20). PolyPhen-2 (Polymorphism Phenotyping v2) predicts possible impact of amino acid substitutions on the structure and function of human proteins using straightforward physical and evolutionary comparative considerations (21).

Results

Sequencing data collection and analysis were successfully performed for the GDF9 and BMP15 genes in all the cases and controls, which included non-familial POF cases; no variant was observed in the coding region of the GDF9 gene of any case and control sample. Four variants of BMP15 gene were observed in cases which included two missense substitutions, one in exon I and the other in exon II position (Table 2). FS 788-ins-TCT was present in 3 cases. Three novel variants were observed in our cohort namely, c.510–512del T, c.165A>T (p.Glu55Asp) and c.538 G>T (p.Aln 180Ser). c.510–512del T is the frameshift variant resulting in elongated chain and by dominant negative effect it impairs the function of normal protein. The c.165A>T (p.Glu.55Asp) is a missense variant and changes the glutamic acid to asparagine at position 55. Provean score for this missense variant was −0.61(cut off score >−2.5) and SIFT prediction score was 0.108 (Cut off >0.05). Both of these scores predicted the neutral effect of this missense variant. This variant was predicted to be benign with a score of 0.007 (sensitivity: 0.96; specificity: 0.75) by PolyPhen 2 software.
Table 2.

Sequence variation in the BMP15 gene in POF patients

Sequence variationAA changeProtein domainNo. of patientsNo. of controls
165A>TGlu55AspExon 11/520/100
538 G>TArg180LeuExon 21/520/100
788insTCTins263LExon 23/520/100
510–512 Del T-Exon 21/520/100
Sequence variation in the BMP15 gene in POF patients In other patients of POF, c.538 G>T (p. Aln 180 Ser) missense variant was observed. This variant also has neutral effect on the protein function as predicted by Provean (0.17) and SIFT score (0.418). PolyPhen 2 also predicted this variant as benign with score of 0.156 (sensitivity: 0.92; specificity: 0.87). The clinical characteristics of the patients carrying BMP15 variants are detailed in table 3. No variant in BMP15 gene was observed in the control group.
Table 3.

Characteristics of patients having BMP15 gene mutation

BMP15 gene variantEthnic originAgeAmenorrhoeaFSH level (mIU/ml)
165A>TIndian31Secondary109
538 G>TIndian33Secondary96
788insTCTIndian28Secondary136
788insTCTIndian32Secondary116
788insTCTIndian35Secondary98
510–512-deletionIndian35Secondary138
Characteristics of patients having BMP15 gene mutation

Discussion

POF is mostly portrayed as a heterogeneous genetic disorder but its etiology still remains elusive. Studies have illuminated the comprehensive role of two oocyte derived growth factors, GDF9 and BMP15, as the main driving force for the proliferation and progression of somatic follicle cells (22). The BMP15 gene plays a vital role in early human folliculogenesis and it is characterized as a strong candidate gene for POF. BMP15 is a member of the large superfamily of the transforming growth factor β (TGFβ) proteins involved in diverse cellular processes during embryonic development and tissue formation (23). The main roles of BMP15 include a) the promotion of follicle maturation from the primordial gonadotropin independent phases of folliculogenesis; b) regulation of follicular GC sensitivity to FSH action; c) prevention of GC apoptosis; d) promotion of oocyte developmental competence; and e) regulation of ovulation quota (9, 24). In the present study, four variants in BMP15 gene were identified of which three variants were novel. c.165A>T (p.Glu55Asp) and c.538 G>T (p.Aln 180Ser) variants has no deleterious effect as predicted by in silico analysis. Previous studies reported different variant C. 538G>A (p.Aln180Thr) at the same position at which we observed C.538G>T (p.Aln180Ser) (11, 25). Similar to our prediction previous reports also shows no deleterious effect of this variant. 788insTCT variant was observed in three patients in our study. This variant has been identified in patients presenting with POF in many previous studies (6, 12, 25, 27). This insertion may be considered as a polymorphism as it was previously identified in controls as well (6, 11, 26, 27). This variant was not found in any of the control subjects. No variant was observed in GDF9 gene in either patients or controls. This is in contrast to the study done by dixit et al. (17) and Laissue et al. (11) which show the GDF9 variants in POF patients.

Conclusion

In conclusion, the present study provided evidence for naturally occurring variants in association with POF and points to the massive importance of BMP15 as a vital candidate gene, which should also be studied in other populations. Although software assessment of the variants reveals their neutral effect, their functional implication cannot be ruled out altogether. Experimental studies should be conducted to determine the real implication of those variations.
  27 in total

1.  Variants of the BMP15 gene in a cohort of patients with premature ovarian failure.

Authors:  D Tiotiu; B Alvaro Mercadal; R Imbert; J Verbist; I Demeestere; A De Leener; Y Englert; G Vassart; S Costagliola; A Delbaere
Journal:  Hum Reprod       Date:  2010-04-03       Impact factor: 6.918

2.  Mutational screening of the coding region of growth differentiation factor 9 gene in Indian women with ovarian failure.

Authors:  Hridesh Dixit; Lakshmi K Rao; Venkata Padmalatha; Murthy Kanakavalli; Mamatha Deenadayal; Nalini Gupta; Baidyanath Chakravarty; Lalji Singh
Journal:  Menopause       Date:  2005-11-08       Impact factor: 2.953

3.  Missense mutations in the BMP15 gene are associated with ovarian failure.

Authors:  Hridesh Dixit; Lakshmi K Rao; Venkata V Padmalatha; Murthy Kanakavalli; Mamata Deenadayal; Nalini Gupta; Baidyanath Chakrabarty; Lalji Singh
Journal:  Hum Genet       Date:  2006-03-01       Impact factor: 4.132

4.  Synergistic roles of bone morphogenetic protein 15 and growth differentiation factor 9 in ovarian function.

Authors:  C Yan; P Wang; J DeMayo; F J DeMayo; J A Elvin; C Carino; S V Prasad; S S Skinner; B S Dunbar; J L Dube; A J Celeste; M M Matzuk
Journal:  Mol Endocrinol       Date:  2001-06

5.  BMP15 mutations in XX gonadal dysgenesis and premature ovarian failure.

Authors:  Susanne Ledig; Albrecht Röpke; Gabriele Haeusler; Bernd Hinney; Peter Wieacker
Journal:  Am J Obstet Gynecol       Date:  2007-09-12       Impact factor: 8.661

6.  Predicting functional effect of human missense mutations using PolyPhen-2.

Authors:  Ivan Adzhubei; Daniel M Jordan; Shamil R Sunyaev
Journal:  Curr Protoc Hum Genet       Date:  2013-01

7.  Analyses of GDF9 mutation in 100 Chinese women with premature ovarian failure.

Authors:  Han Zhao; Yingying Qin; Ertug Kovanci; Joe Leigh Simpson; Zi-Jiang Chen; Aleksandar Rajkovic
Journal:  Fertil Steril       Date:  2007-05-07       Impact factor: 7.329

8.  Hypergonadotropic ovarian failure associated with an inherited mutation of human bone morphogenetic protein-15 (BMP15) gene.

Authors:  Elisa Di Pasquale; Paolo Beck-Peccoz; Luca Persani
Journal:  Am J Hum Genet       Date:  2004-05-10       Impact factor: 11.025

9.  Variation in bone morphogenetic protein 15 is not associated with spontaneous human dizygotic twinning.

Authors:  Zhen Zhen Zhao; Jodie N Painter; James S Palmer; Penelope M Webb; Nicholas K Hayward; David C Whiteman; Dorret I Boomsma; Nicholas G Martin; David L Duffy; Grant W Montgomery
Journal:  Hum Reprod       Date:  2008-07-09       Impact factor: 6.918

10.  Predicting the functional effect of amino acid substitutions and indels.

Authors:  Yongwook Choi; Gregory E Sims; Sean Murphy; Jason R Miller; Agnes P Chan
Journal:  PLoS One       Date:  2012-10-08       Impact factor: 3.240

View more
  12 in total

1.  Loss of the E2 SUMO-conjugating enzyme Ube2i in oocytes during ovarian folliculogenesis causes infertility in mice.

Authors:  Amanda Rodriguez; Shawn M Briley; Bethany K Patton; Swamy K Tripurani; Kimal Rajapakshe; Cristian Coarfa; Aleksander Rajkovic; Alexandra Andrieux; Anne Dejean; Stephanie A Pangas
Journal:  Development       Date:  2019-12-02       Impact factor: 6.868

Review 2.  Genetics of human female infertility†.

Authors:  Svetlana A Yatsenko; Aleksandar Rajkovic
Journal:  Biol Reprod       Date:  2019-09-01       Impact factor: 4.285

3.  "Evaluation of four genes associated with primary ovarian insufficiency in a cohort of Mexican women".

Authors:  K J Juárez-Rendón; J E García-Ortiz
Journal:  J Assist Reprod Genet       Date:  2018-06-18       Impact factor: 3.412

4.  Control of ovarian follicle development by TGFβ family signaling.

Authors:  Bethany K Patton; Surabhi Madadi; Stephanie A Pangas
Journal:  Curr Opin Endocr Metab Res       Date:  2021-03-11

Review 5.  GDF-9 and BMP-15 direct the follicle symphony.

Authors:  Alexandra Sanfins; Patrícia Rodrigues; David F Albertini
Journal:  J Assist Reprod Genet       Date:  2018-07-23       Impact factor: 3.412

Review 6.  Inflamm-Aging: A New Mechanism Affecting Premature Ovarian Insufficiency.

Authors:  Yaoqi Huang; Chuan Hu; Haifeng Ye; Ruichen Luo; Xinxin Fu; Xiaoyan Li; Jian Huang; Weiyun Chen; Yuehui Zheng
Journal:  J Immunol Res       Date:  2019-01-02       Impact factor: 4.818

Review 7.  Unraveling the Balance between Genes, Microbes, Lifestyle and the Environment to Improve Healthy Reproduction.

Authors:  Valeria D'Argenio; Lara Dittfeld; Paolo Lazzeri; Rossella Tomaiuolo; Ennio Tasciotti
Journal:  Genes (Basel)       Date:  2021-04-20       Impact factor: 4.141

Review 8.  Onco-fertility and personalized testing for potential for loss of ovarian reserve in patients undergoing chemotherapy: proposed next steps for development of genetic testing to predict changes in ovarian reserve.

Authors:  Bei Sun; John Yeh
Journal:  Fertil Res Pract       Date:  2021-06-30

9.  Deletion of Gremlin-2 alters estrous cyclicity and disrupts female fertility in mice†.

Authors:  Robert T Rydze; Bethany K Patton; Shawn M Briley; Hannia Salazar Torralba; Gregory Gipson; Rebecca James; Aleksandar Rajkovic; Thomas Thompson; Stephanie A Pangas
Journal:  Biol Reprod       Date:  2021-11-15       Impact factor: 4.161

Review 10.  Effectiveness of Cotreatment with Kuntai Capsule and Climen for Premature Ovarian Failure: A Meta-Analysis.

Authors:  Qianwen Ma; Yong Tan; Genlin Mo
Journal:  Evid Based Complement Alternat Med       Date:  2020-02-19       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.